PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide
|
EQS-News: PL BioScience GmbH
/ Key word(s): Conference/Alliance
PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide
Aachen, Germany, 8 May 2025 – PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced the first-ever production of an artificial HPL cell culture solution. In partnership with the Korean biotech DewCell Biotherapeutics (DewCell), the first company to generate artificial platelets from stem cells in a reactor, PL BioScience has developed a proprietary method to transform these lab-grown platelets into a powerful cell culture supplement. Produced in Germany with raw material from DewCell, this new technology offers a scalable, safe, and animal-free alternative to Fetal Calf/Bovine Serum (FCS/FBS) and donor-derived, natural HPL for regenerative medicine, cell therapy, and biopharma applications. A patent for the process has been filed. “Cell culture innovation is crucial for advancing modern medicine, drug discovery, and understanding complex biological systems,” said Dr. Hatim Hemeda, Chief Executive Officer of PL BioScience. “We are proud to contribute to the field with the very first, scalable artificial HPL solution that, in the mid-term, can be produced in a nearly unlimited supply to meet the growing biopharmaceutical industry needs.” “We are confident that the combination of DewCell's innovative technology and our cell culture expertise will usher in a new era in the field of regenerative medicine and cell therapy manufacturing,” he added. Dr. Hemeda will present the innovative new technology in an oral presentation at the International Society for Cell & Gene Therapy (ISCT) conference in New Orleans: HPL is a safe, high-performance cell culture supplement that can be used as an alternative to FBS/FCS. HPL is manufactured from donated human blood platelets that are outdated and no longer safe for transfusion, making them a sustainable but limited source to produce HPL. With its proprietary technology for the synthetic production of HPL in conjunction with DewCell’s artificial platelet technology, PL BioScience can overcome this limitation and provides a fully scalable, high-performing cell culture supplement for biopharmaceutical applications. About Human Platelet Lysate: Human Platelet Lysate (HPL) is an innovative, human-derived cell culture supplement used to support the growth and expansion of cells in research and clinical development, particularly in cell therapy, stem cell, and regenerative medicine applications. Natural HPL is produced from donated human blood platelets that are no longer suitable for transfusion and would otherwise be discarded – making it a sustainable yet limited alternative to animal-derived cell culture supplements. A next-generation, fully artificial alternative made from lab-grown platelets has been developed by PL BioScience to secure the future supply. In cell culture, HPL provides essential growth factors and nutrients that promote healthy, robust cell proliferation. Compared to conventional products such as Fetal Bovine Serum (FBS), which is harvested from unborn calves, HPL delivers more consistent results in cell growth, is free from animal-derived pathogens, and aligns with the increasing demand for animal-free and ethically responsible laboratory practices. ELAREM™, PL BioScience’s line of xeno-free HPL products, can be used from early-stage research to the production of cell-based therapies under Good Manufacturing Practice (GMP) conditions for the treatment of patients. About PL BioScience: PL BioScience GmbH, a life science company located in Aachen, Germany, specializes in the production and development of Human Platelet Lysate (HPL). The Company has pioneered proprietary technology to produce fully artificial HPL allowing for a fully lab-made, scalable supply of HPL in the future. PL BioScience currently offers a comprehensive portfolio of donor-derived, natural HPL products tailored for a range of applications. From academic and preclinical research to cell therapy and biopharmaceutical manufacturing, ELAREM™ ensures seamless translations of regenerative medicine breakthroughs – from the lab to patients in need. With ELAREM™ Ultimate-FD PLUS, PL BioScience produces the only globally patented gamma-irradiated HPL product. For more information on PL BioScience and the ELAREM™ product offerings, visit: https://www.pl-bioscience.com/ Contact:
08.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | PL BioScience GmbH |
| Dennewartstr. 25-27 | |
| 52068 Aachen | |
| Germany | |
| E-mail: | info@pl-bioscience.com |
| Internet: | www.pl-bioscience.com |
| EQS News ID: | 2133392 |
| End of News | EQS News Service |
|
|
2133392 08.05.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.